Literature DB >> 11870919

Selective infection of E. coli as a function of a specific molecular interaction.

Nina Nilsson1, Fredrik Karlsson, Jasna Rakonjac, Carl A K Borrebaeck.   

Abstract

Selective infection of phage is when the bacterial infection depends on the specific molecular interaction between an antigen and a phage-displayed protein sequence such as an antibody. Engineering of the normal infection into pathways, directed by a specific protein--protein interaction, has raised several mechanistic questions. Here, we address the type of display and the affinity between the interacting pairs. The deleted phage R408d3 was used for the first time in selective infection and was shown to exhibit a superior performance compared to the VCSM13 phage. Furthermore, the affinity between the interacting pairs also affected the selective infection process and a correlation between affinity and infection efficiency was detected, thus implying that selective infection is the method of choice for selection of rare high-affinity interactions in molecular libraries. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11870919     DOI: 10.1002/jmr.557

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  3 in total

1.  The mechanism of bacterial infection by filamentous phages involves molecular interactions between TolA and phage protein 3 domains.

Authors:  Fredrik Karlsson; Carl A K Borrebaeck; Nina Nilsson; Ann-Christin Malmborg-Hager
Journal:  J Bacteriol       Date:  2003-04       Impact factor: 3.490

2.  Intra-domain phage display (ID-PhD) of peptides and protein mini-domains censored from canonical pIII phage display.

Authors:  Katrina F Tjhung; Frédérique Deiss; Jessica Tran; Ying Chou; Ratmir Derda
Journal:  Front Microbiol       Date:  2015-04-28       Impact factor: 5.640

Review 3.  Prokaryotic expression of antibodies and affibodies.

Authors:  Luis Angel Fernández
Journal:  Curr Opin Biotechnol       Date:  2004-08       Impact factor: 9.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.